SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is seeing a significant rally following a CMS announcement that finalizes 2027 Medicare Advantage payment rates at a higher-than-expected increase, alleviating major industry uncertainty. The community is actively debating the sustainability of these gains, with many investors viewing the news as a long-awaited relief catalyst while others remain cautious of ongoing sector volatility and regulatory headwinds.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is currently seeing intense debate among investors as the stock faces downward pressure, with bears highlighting concerns over certification timelines, testing delays, and competitive challenges in the eVTOL space. Meanwhile, bulls continue to emphasize the company's long-term potential, citing strategic partnerships and upcoming operational milestones as catalysts that could drive a significant recovery.

FuboTV, Inc. is a consumer-first live TV streaming company with the mission of delivering premium sports, news and entertainment programming that offers greater choice, flexibility and value. The company was founded by David Gandler, Alberto Horihuela Suarez, and Sung Ho Choi on February 20, 2009 and is headquartered in New York, NY.

fuboTV Inc - Ordinary Shares - Class A

fuboTV Inc

FuboTV is experiencing significant volatility and downward pressure following a recent reverse stock split, sparking intense debate among community members who are split between betting on a potential short squeeze and warning of further downside. Traders are actively monitoring management's silence on guidance and the stock's proximity to pre-split lows, with many users expressing frustration over long-term performance while others hunt for technical entry points.

Avis Budget Group, Inc. engages in the provision of vehicle sharing and rental services. It operates through the Americas and International segments. The Americas segment includes vehicle rental and car sharing operations in North America, South America, Central America, and the Caribbean. The International segment is involved in vehicle rental and car sharing operations in Europe, the Middle East, Africa, Asia, and Australasia. The company was founded in 1946 and is headquartered in Parsippany, NJ.

Avis Budget Group Inc

Avis Budget Group is experiencing significant downward pressure as investors react to a debt offering, raising concerns over the company's financial leverage and capital management. Meanwhile, the community remains deeply divided, with some traders betting on further downside due to fundamental weaknesses while others identify the sharp sell-off as a potential deep-value opportunity.

Klarna Group Plc is a global digital bank and flexible payments provider. It operates through an AI-powered payments and commerce network that empowers people to pay smarter, with a mission to be available everywhere, for everything. The company was founded by Gustav Erik Niklas Adalberth, Karl Anders Victor Jacobsson, and Sebastian Marcin Siemiatkowski in 2005 and is headquartered in London, the United Kingdom.

Klarna Group plc

Klarna is facing intense community debate as investors weigh significant insider stock purchases by leadership against concerns regarding high short interest and potential volatility following the expiration of lock-up periods. While some participants are betting on a short squeeze driven by dwindling share availability, others remain cautious, focusing on the company's path to profitability and upcoming legal catalysts.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is under intense community scrutiny following a significant patent infringement loss in China's Supreme Court, fueling speculation about a potential billion-dollar settlement with Xiao-I AI. While traders remain wary of the stock's recent performance compared to broader tech peers, the community is actively debating whether Apple will move to settle the legal dispute quickly to avoid further disruptions to its Chinese operations.

Viridian Therapeutics, Inc. is a biopharmaceutical company that develops medicines for autoimmune and rare diseases. It uses antibody discovery and protein engineering to create new therapies. The company is advancing late-stage IGF-1R therapies for thyroid eye disease (TED) and developing a potential TSHR-targeted treatment for TED and Graves’ disease. In addition, it is developing FcRn inhibitors, including VRDN-006 and VRDN-008, for multiple autoimmune diseases. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.

Viridian Therapeutics Inc

Viridian Therapeutics is facing significant downward pressure following the release of Phase 3 clinical trial data for its thyroid eye disease candidate, elegrobart, which investors deemed underwhelming compared to Amgen's established Tepezza. While some analysts maintain a bullish long-term outlook citing potential differentiation in dosing and subcutaneous delivery, the market is currently reacting with heavy put-option hedging and skepticism regarding the treatment's competitive profile.

Taseko Mines Ltd. operates as a mining company which engages in the acquisition, development, and operation of mineral deposits. It holds interest in the Gibraltar, Florence Copper, Aley Niobium, Yellowhead, New Prosperity, and Harmony projects. The company was founded on April 15, 1966 and is headquartered in Vancouver, Canada.

Taseko Mines Ltd.

Taseko Mines is trending as investors bet on the companys transition into a major U.S. copper producer, with the Florence Copper project nearing commercial production and poised to double output. The community is actively discussing the potential for a structural copper supply shortage, the strategic importance of North American assets for AI and green energy, and the stock's significant upside potential as it moves toward operational milestones.

Himax Technologies, Inc. is a semiconductor solution provider dedicated to display imaging processing technologies. It operates through the Driver Integrated Circuit and Non-Driver Products segments. The company's products include display drivers, timing controllers, wafer level optics, video and display technology solutions, liquid crystal over silicon silicon, complementary metal-oxide semiconductor image sensor, and power integrated circuit. Its products used in TVs, laptops, monitors, mobile phones, tablets, digital cameras, car navigation, virtual reality (VR) devices and many other consumer electronics devices. Himax Technologies was founded by Biing Seng Wu and Jordan Wu on June 12, 2001 and is headquartered in Tainan, Taiwan.

Himax Technologies - ADR

Himax Technologies, Inc.

Himax Technologies is trending as investors weigh its potential role in the Co-Packaged Optics supply chain for AI data centers against persistent concerns over weak legacy display driver demand. The community remains divided, with some betting on a long-term turnaround fueled by strategic partnerships, while others express frustration over stagnant performance and repetitive earnings narratives.

Ouster, Inc. engages in the provision of high resolution digital lidar sensors that offer advanced 3D vision to machinery, vehicles, robots, and fixed infrastructure assets. The company was founded by Angus Pacala and Mark Frichtl on June 30, 2015 and is headquartered in San Francisco, CA.

Ouster Inc - Ordinary Shares - Class A

Ouster is trending following the acquisition of StereoLabs, a move that positions the company as a leader in physical AI by unifying lidar hardware with advanced stereo vision and AI perception software. Investors are focused on the strategic expansion into robotics and industrial sectors, alongside the combined company's positive EBITDA path and access to a significantly larger customer base.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>In Kentucky, TeraWulf has acquired a former industrial site in Hawesville, which has approximately 480 MW of existing power availability.</li><li>In Maryland, where TeraWulf is headquartered, the company has acquired the Morgantown Generating Station.</li><li>This expanded development pipeline supports its growth strategy targeting 250 to 500 MW of new contracted capacity annually.</li></ul>Shares of TeraWulf (<a href="https://stocktwits.com/symbol/WULF">WULF</a>) surged more than 10% during extended hours of trading on Monday after the company announced that it is expanding its digital and power infrastructure portfolio.&nbsp;The company said it is expanding its portfolio through the acquisition of two strategically located brownfield infrastructure sites in Hawesville, Kentucky and Charles County, Maryland.<h2 class="st-heading-2">Details</h2>TeraWulf said these acquisitions added about 1.5 gigawatts (GW) of capacity to its portfolio and advanced the company’s strategy of developing energy-advantaged locations with near-term power availability, long-term scalability, and the ability to support customer demand and broader grid needs.In Kentucky, TeraWulf has acquired a former industrial site in Hawesville. The site includes more than 250 buildable acres for compute capacity and offers immediate access to robust power infrastructure, the statement said.&nbsp;The Hawesville site has approximately 480 megawatts (MW) of existing power availability, with the potential to further expand over time. Development is expected to occur in phases, allowing TeraWulf to scale efficiently alongside customer demand.In Maryland, where TeraWulf is headquartered, it has acquired the Morgantown Generating Station. The acquisition establishes TeraWulf’s presence in the Pennsylvania-New Jersey-Maryland (PJM) market and reinforces the company’s strategy of reinvesting in existing energy assets to support grid reliability and long-term economic activity.<h2 class="st-heading-2">Portfolio Expansion</h2>With the addition of these sites, TeraWulf’s infrastructure portfolio now totals approximately 2.8 GW across five sites, including 642.5 MW of contracted capacity and 2.2 GW of owned pipeline capacity.This expanded development pipeline supports its growth strategy targeting 250 to 500 MW of new contracted capacity annually, aligned with customer demand, power availability, and regional grid conditions.“These acquisitions reflect our strategy of reinvesting in existing energy infrastructure to support grid reliability, long-term economic activity, and responsible growth,” said Paul Prager, Chairman and Chief Executive Officer of TeraWulf.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around WULF trended in ‘extremely bullish’ territory amid ‘high’ message volume.&nbsp;One bullish user said that “2 additional site announcement today DOUBLES the AI/HPC capacity”.&nbsp;<stembedurl>https://stocktwits.com/AllMarkets/message/643740254</stembedurl>Shares in the company have jumped more than 200% over the past 12 months.&nbsp;&nbsp;

 In this photo illustration, the TeraWulf (Tera Wulf) logo is seen displayed on a smartphone screen.

Why Is TeraWulf Stock Rallying More Than 10% After Hours?

With the addition of these sites, TeraWulf’s infrastructure portfolio now totals approximately 2.8 GW across five sites.

Equity

<ul class="summary-bullets"><li>H.C. Wainwright said KRRO-121 adds a second, "independently risk-mitigated asset as a call option."</li><li>Piper Sandler said it left the company’s analyst day on Tuesday with "strong conviction" for KRRO-121's probability of success.</li><li>Oppenheimer upgraded Korro Bio to ‘Outperform’ from ‘Perform’ with a $22 price target.</li></ul>Shares of Korro Bio Inc. (KRRO) jumped 13% on Thursday after multiple analysts upgraded the stock on optimism about the company’s new development candidate KRRO-121.Korro is now looking to study the drug in the treatment of hyperammonemia. The company said on Tuesday that it intends to file an application in the second half of 2026 to begin its first in-human trial for the candidate.<h2 class="st-heading-2">Analysts Chime In</h2>H.C. Wainwright upgraded Korro Bio to ‘Buy’ from ‘Neutral’ with a $20 price target, according to TheFly. The firm said KRRO-121 adds a second, "independently risk-mitigated asset as a call option."Korro shares are trading near a zero enterprise value, the analyst told investors in a research note. H.C. Wainwright believes KRRO-121 is not a read-through from KRRO-110,"so this is a truly independent shot on goal."Piper Sandler analyst Yasmeen Rahimi on Wednesday also upgraded Korro Bio to ‘Overweight’ from ‘Neutral’ with a price target of $30, up from $11. Piper said it left the company’s analyst day on Tuesday with "strong conviction" for KRRO-121's probability of success, it said.The firm is bullish ahead of KRRO-121's new drug filing in the second half of 2026, saying there is a "clear precedence for a regulatory path."Oppenheimer also upgraded Korro Bio to ‘Outperform’ from ‘Perform’ with a $22 price target. The firm believes the company's probability of success is now reset and that KRRO-121 offers a fresh, interesting story wherein RNA editing can thrive. The firm sees potential for significant upside.<h2 class="st-heading-2">Pivot From KRRO-110</h2>In November, Korro said that in its <a href="https://stocktwits.com/news-articles/markets/equity/korro-bio-stock-crashes-over-75-after-hours-on-drug-failure-downgrades-and-layoffs/cLPBNsbREdA">trial</a> evaluating KRRO-110 in the genetic disorder called Alpha-1 Antitrypsin Deficiency (AATD), it achieved functional protein production with a single administration, but it did not achieve the protein levels projected based on preclinical data.The lower-than-expected results prompted a 34% reduction in working and the company subsequently opted KRRO-121 as its next development candidate, for the potential treatment of patients with hyperammonemia.Hyperammonemia is a critical metabolic condition defined by abnormally elevated blood ammonia levels, commonly resulting from liver failure (cirrhosis) or inherited urea cycle disorders. It causes acute, severe neurological impairment—including encephalopathy, seizures, coma, and cerebral edema—and requires immediate medical intervention to prevent fatal brain damage.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around KRRO stock rose from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume increased from ‘high’ to ‘extremely high’ levels.A Stocktwits user said that a strong momentum setup is shaping up, adding that buyers are defending these levels and pushing higher.<stembedurl>https://www.stocktwits.com/topstockalerts/message/643304339</stembedurl><a href="https://stocktwits.com/symbol/KRRO">KRRO shares</a> have dropped 60% in the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/trump-administration-reportedly-ready-to-lay-out-crypto-law/cmyikhjR41I">Trump Administration Reportedly Ready To Lay Out Crypto Rules</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

KRRO Shares Jump 13% On Analyst Upgrades — What’s Driving The Optimism?

The company said on Tuesday that it intends to file an application in the second half of 2026 to begin its first in-human trial for its new development candidate KRRO-121. 

<ul class="summary-bullets"><li>The offering includes 34.8 million shares at $5.75, the stock’s closing price on Tuesday.</li><li>Medtronic’s investment is expected to give it a post-offering ownership stake of between 16% and 19.99%.</li><li>Proceeds from the transactions will be used to support Anteris’ clinical strategy, including&nbsp; R&amp;D at v2vmedtech.</li></ul>Shares of Anteris Technologies Global Corp. (AVR) jumped sharply in pre-market trading on Wednesday after the structural heart specialist unveiled a $200 million equity raise alongside a sizable strategic investment from healthcare technology heavyweight Medtronic.<a href="https://stocktwits.com/symbol/AVR">AVR shares</a> were up around 17% at the time of writing and were on track to open at their highest levels since March 2025.Anteris announced a proposal to raise $200 million via a public offering of its common stock and grant underwriters a 30-day option to purchase up to an additional $30 million of shares at the public offering price.In a separate release, the company said the offer is to sell around 34.8 million shares at $5.75, the stock’s closing price on Tuesday.<h2 class="st-heading-2">Medtronic Investment</h2>Alongside the public offering, Anteris entered into a stock purchase agreement with Medtronic plc (MDT). Under the deal, Medtronic, through a wholly owned unit, will invest up to $90 million in Anteris common stock via a private placement priced in line with the public offering. The transaction is expected to give Medtronic a post-offering ownership stake of between 16% and 19.99% in Anteris.Proceeds from the transactions will be used to support Anteris’ clinical strategy, including continued patient recruitment and execution of the global PARADIGM pivotal trial for the DurAVR Transcatheter Heart Valve (THV) in severe aortic stenosis, expanding manufacturing capacity, and funding ongoing research and development (R&amp;D) at v2vmedtech, a privately owned medical technology company.The DurAVR THV is a biomimetic valve designed to mimic the performance of a healthy aortic valve.&nbsp;<h2 class="st-heading-2">What Is Retail Saying?</h2>On Wednesday, retail sentiment for AVR flipped to ‘extremely bullish’ from ‘bearish’ a day earlier, while message volumes increased to ‘extremely high’ from ‘normal’ on Stocktwits. AVR was among the top trending tickers on the platform at the time of writing.<img src="https://news.stocktwits-cdn.com/AVR_jpg_6c056947d5.webp" alt="AVR.jpg">One user expects the stock to hit $20 on the ‘bullish news’.<stembedurl>https://stocktwits.com/Redrooster79/message/642383722</stembedurl>However, another user was slightly skeptical about the dilution.<stembedurl>https://stocktwits.com/Rvazstocksfl/message/642363903</stembedurl>AVR stock has declined more than 4% over the past year but has gained around 12% so far in 2026.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-is-nvidia-stock-rising-in-premarket-today/cmUDZxrR4Oz">Why Is Nvidia Stock Rising In Premarket Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising chart and reflection of business buildings: stock photo courtesy of Yuichiro Chino via Getty Images

Why Did AVR Stock Surge Pre-Market Today? 

The company unveiled a $200 million dilution alongside a $90 million investment from healthcare technology heavyweight Medtronic.

AVR Stock Pops Pre-Market: Medtronic Backs $200M Capital Raise To Fund Key Trial

<ul class="summary-bullets"><li>Ocular Therapeutix had reportedly rejected Sanofi’s initial takeover bid in September.</li><li>If the acquisition goes through, it would bolster Sanofi’s footprint in ophthalmology.</li><li>Sanofi recently acquired Dynavax to boost its vaccine portfolio.</li></ul>Ocular Therapeutix (OCUL) was back on retail’s radar, with the stock surging 13% in premarket trading on Thursday, after reports emerged that French pharmaceutical giant Sanofi (SNY) is preparing an offer to acquire the American biopharmaceutical firm.According to French publication La Lettre, the renewed interest comes after Ocular Therapeutix rejected Sanofi’s initial takeover bid in September, when the group offered $16 per share, a substantial premium to Ocular’s then-trading price of about $10.50.<a href="https://stocktwits.com/symbol/OCUL">OCUL shares</a> have been on a downtrend lately, declining in 11 of the last 13 sessions. <a href="https://stocktwits.com/symbol/SNY">SNY stock</a> was down 0.4% in pre-open trade.<h2 class="st-heading-2">Acquisition Rationale</h2>If the acquisition goes through, it would bolster Sanofi’s footprint in ophthalmology, particularly in age-related macular degeneration, which affects the central part of the retina.At the same time, it could support Sanofi’s push into combination therapies, with Ocular’s treatments, such as Dextenza for ocular inflammation, potentially pairing well with existing drugs like Dupixent, given studies suggesting links between chronic skin conditions and eye disorders such as cataracts.<h2 class="st-heading-2">Sanofi’s Acquisition Spree</h2>Sanofi has been ramping up its strategy to add to its portfolio through key acquisitions over the last few months. In late December, Sanofi signed an agreement to acquire vaccine maker Dynavax Technologies Corp (DVAX) in a <a href="https://stocktwits.com/news-articles/markets/equity/why-did-dynavax-stock-surge-38-in-premarket-today/cLesA4mREHU">$2.2 billion deal</a> aimed at strengthening its adult immunization portfolio. The transaction will strengthen Sanofi’s global vaccines business by bringing in Dynavax’s approved adult hepatitis B vaccine, HEPLISAV-B, along with a differentiated shingles vaccine.In June, Sanofi agreed to <a href="https://stocktwits.com/news-articles/markets/equity/sanofi-to-buy-blueprint-medicines-for-up-to-9.5-billion/chkoCYnRbHc">acquire Blueprint</a> Medicines for about $9.1 billion to deepen its presence in the cure for rare immunological diseases. The acquisition added Ayvakit/Ayvakyit, the only approved treatment for systemic mastocytosis, along with pipeline assets including Elenestinib and BLU-808 to Sanofi’s portfolio.<h2 class="st-heading-2">How Did Retail React?</h2>Retail sentiment for OCUL on Stocktwits remained in the ‘extremely bullish’ zone over the past 24 hours, accompanied by ‘extremely high’ message volumes.<figure class="image"><img src="https://news.stocktwits-cdn.com/OCUL_jpg_9ede93e8cf.webp" alt="OCUL.jpg" width="928" height="100"><figcaption>OCUL's Sentiment Meter and Message Volumes at Premarket on Jan. 15, 2026 | Source: Stocktwits</figcaption></figure>One user sees upside in OCUL stock due to the offer.<stembedurl>https://stocktwits.com/scholar9/message/641880419</stembedurl>OCUL shares have gained around 34% over the past year.Read also: <a href="https://stocktwits.com/news-articles/equity/markets/nasdaq-sp500-futures-pause-nvda-tsm-msft-cvx-stocks-to-watch/cmU1L2fR47N">Nasdaq, S&amp;P 500 Futures Pause Ahead Of Major Bank Earnings, Jobless Claims: Why NVDA, TSM, CVX, MSFT, AMZN Are On Traders' Radar Today</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

A candlestick chart can be seen in a trading platform on a smartphone. Top U.S. firms announced record buybacks this year. (Photo by Silas Stein/picture alliance via Getty Images)

Why Did OCUL Stock Jump 13% In Pre-Market Today?

French pharmaceutical giant Sanofi is preparing an offer to acquire the American biopharmaceutical firm, according to a report by French publication La Lettre.

OCUL Stock Back On Retail Radar With Sanofi Takeover Speculation Resurfacing

<ul class="summary-bullets"><li>flyExclusive will begin installing Starlink on its fleet to provide high-speed, low-latency internet connection at high altitudes.&nbsp;</li><li>The company will also provide sales, installation, and support services to third-party aircraft owners and operators.&nbsp;</li><li>Starlink installations on flyExclusive’s Challenger 350 fleet will begin in early 2026.</li></ul>flyExclusive, Inc. (FLYX) shares more than doubled on Thursday after the private jet operator announced an authorized dealership agreement with SpaceX’s Starlink.As per the agreement, flyExclusive said it will begin installing Starlink on its fleet to provide high-speed, low-latency internet connection at high altitudes.The aviation company said that installations on its Challenger 350 fleet will kick off in early 2026.Shares of FLYX rallied over 130% at the time of writing.<h2 class="st-heading-2">The Starlink Deal</h2>Apart from providing Starlink connectivity on its own jets, flyExclusive will also provide sales, installation, and support services to third-party aircraft owners and operators. The company said that the move expands its Maintenance, Repair, and Operations (MRO) capabilities.flyExclusive’s deal with Starlink is aimed at improving streaming quality, real-time communications, and consistent VPN performance at high altitudes on all its jets.Starlink’s 310 Mbps connectivity with low latency will support HD video conferencing, streaming, large file transfers, and modern productivity tools on flights.The Starlink dealership aligns with the company’s technology investment, customer experience, and fleet modernization plans, the company said.“Connectivity is no longer a luxury. It is a core part of the passenger experience,” said Matt Lesmeister, Chief Operating Officer of flyExclusive. “Becoming a Starlink aviation dealer strengthens our MRO capabilities while raising the bar across our fleet.”<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/FLYX">FLYX shares</a> jumped to ‘extremely bullish’ from ‘bullish’ sentiment a day ago as message volumes spiked to ‘extremely high’.<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_01_08_at_9_39_06_PM_png_6f11fe3664.webp" alt="On Stocktwits, retail sentiment around FLYX shares jumped to ‘extremely bullish’ from ‘bullish’ sentiment a day ago as message volumes spiked to ‘extremely high’." width="1285" height="148"></figure>&nbsp;One bullish user praised the deal, saying the stock could jump to $9.00 levels by the end of the trading session. Shares of FLYX traded around $7.28 at the time of writing.<stembedurl>https://stocktwits.com/come_litaliano/message/641194617</stembedurl>&nbsp;FLYX stock has climbed over 120% in the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also Read: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-crmd-stock-crash-28-today/cmUbayOR45b">Why Did CRMD Stock Crash 28% Today?</a> &nbsp;

A SpaceX Falcon 9 rocket carrying a payload of 24 Starlink internet satellites soars into space after launching from Vandenberg Space Force Base on July 18, 2025, seen from Santee, California.

FLYX Stock Surged Over 130% Today — What’s The SpaceX Connection?

Private jet operator flyExclusive announced an authorized dealership agreement with SpaceX’s Starlink on Thursday.

FLYX Stock Surges 130% — What’s The SpaceX Connection?

Private jet operator flyExclusive announced an authorized dealership agreement with SpaceX’s Starlink on Thursday. 

<ul class="summary-bullets"><li>For Tether, the launch represents the first real-world deployment of its WDK, designed to help platforms roll out wallets without centralized custodians.</li><li>MoonPay, a crypto payments company,&nbsp;will support on- and off-ramps, allowing users to move between crypto and traditional payment methods.</li><li>The goal for Rumble is to cut out intermediaries such as banks, ad networks, and payment processors.</li></ul>Rumble Inc. (RUM) shares rose over 4% on Wednesday after the company partnered with Tether to launch Rumble Wallet, a non-custodial crypto wallet that integrates digital asset payments directly into its video-sharing platform.At present, the wallet supports Bitcoin, Tether (USDT), and Tether Gold (XAUt). By integrating crypto payments at the platform level, Rumble aims to cut out intermediaries such as banks, ad networks, and payment processors. The Rumble Wallet is built using Tether’s Wallet Development Kit (WDK).For Tether, the launch represents the first real-world deployment of its WDK, designed to help platforms roll out wallets without centralized custodians.&nbsp;Crypto payments company, MoonPay, will support on- and off-ramps, allowing users to move between crypto and traditional payment methods, including credit cards, Apple Pay, PayPal, and Venmo.“Peer-to-peer payments powered by crypto are the future of the internet economy. Rumble is one of the first major platforms to adopt this model, giving creators the ability to get paid instantly in stablecoins or Bitcoin and easily move in and out of fiat,” said Ivan Soto-Wright, CEO of MoonPay.<h2 class="st-heading-2">Rumble’s Growth Strategy</h2>The wallet launch comes as Rumble, a video streaming and cloud company that hosts U.S. President Donald Trump’s Truth Social platform, advances its broader growth strategy. The company recently confirmed it filed an S-4 with U.S. regulators for its proposed $767 million all-stock merger with German data center operator Northern Data, a deal first announced in November.If completed, the transaction would transform Rumble into a full-stack cloud services provider with a sizable data center footprint across the U.S. and Europe and access to more than 22,000 Nvidia GPUs. Tether has also committed to a $150 million GPU leasing agreement with the combined entity, positioning Rumble to benefit from surging demand for AI-focused data center infrastructure.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits flipped to ‘extremely bullish’ from ‘bearish’ a day earlier, amid ‘high’ message volumes. <a href="https://stocktwits.com/symbol/RUM">RUM</a> was among the top trending stocks at the time of writing.<img src="https://news.stocktwits-cdn.com/RUM_jpg_b24d50a5b1.webp" alt="RUM.jpg">One user expects the stock to climb over $10. It is currently trading near $7.<stembedurl>https://stocktwits.com/Nopainnogain99/message/641062575</stembedurl>Over the past year, the stock has declined nearly 50%.Read Also: <a href="https://stocktwits.com/news-articles/markets/equity/alaska-airlines-places-record-order-for-boeing-737-10-787-jets/cmxzcYDR429">Alaska Airlines Places Record Order for Boeing 737-10, 787 Jets</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 2025/02/03: In this photo illustration, the Rumble logo is seen displayed on a smartphone screen.

Rumble Rallies After Unveiling Tether-Powered Crypto Wallet – Retail Expects Stock To Surpass The $10 Mark

The wallet, built with Tether’s Wallet Development Kit, currently supports Bitcoin, Tether (USDT), and Tether Gold (XAUt).

Zeta Global, an AI marketing firm, said on Monday it has entered into a strategic collaboration with OpenAI to integrate its advanced AI models into its marketing platform named Athena, sending shares of Zeta Global soaring 9% in after-market trading.&nbsp;Zeta will also have the opportunity for early access to new OpenAI models and features, enabling deeper integration with the latest advancements in AI, it said.&nbsp;The companies will align Athena's product roadmap with advances in OpenAI models, accelerating how enterprise teams get decision-ready answers inside their daily workflows, it stated.&nbsp;<h2 class="st-heading-2">Athena Platform</h2>Zeta’ Athena platform personalizes marketers’ workspaces with voice-activated answers. It allows marketers at the platform to interact with data and automate their tasks. Zeta unveiled its Athena platform in October last year.&nbsp;Zeta plans to launch Athena to all customers by the end of the first quarter of (Q1) 2026.“Zeta shows how advanced AI moves beyond insight and into action,” said Giancarlo ‘GC’ Lionetti, Chief Commercial Officer at OpenAI. “By working together, we are bringing agentic intelligence directly into everyday marketing workflows, helping enterprises move faster and act with confidence.”TKO Group Holdings, Inc., the premium sports and entertainment company that comprises UFC and WWE, was part of Athena's Early Access Program.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around ZETA trended in ‘extremely bullish’ territory amid ‘high’ message volumes.&nbsp;One bullish user predicted stock to hit $30 on Tuesday.&nbsp;<stembedurl>https://stocktwits.com/Tetsuo_shima/message/640886808</stembedurl>Zeta will also have the opportunity for early access to new OpenAI models and features, enabling deeper integration with the latest advancements in AI, it said.&nbsp;The companies will align Athena's product roadmap with advances in OpenAI models, it added.&nbsp;Get updates to this developing story directly on Stocktwits. &nbsp;

In this photo illustration, a person holds a smartphone displaying the logo of Zeta Global Holdings Corp. 

Zeta Global Shares Rose After It Deepens Collaboration with OpenAI 

Zeta will also have the opportunity for early access to new OpenAI models and features, enabling deeper integration with the latest advancements in AI. 

<ul class="summary-bullets"><li>The outlook assumes net sales for Linzess will be between $1.125 billion and $1.175 billion in FY2026.</li><li>U.S. FDA had approved Ironwood’s Linzess capsules for pediatric patients, in November.</li><li>Linzess is the first treatment approved for the irritable bowel syndrome with constipation in pediatric patients.</li></ul>Shares of Ironwood Pharmaceuticals (<a href="https://stocktwits.com/symbol/IRWD">IRWD</a>) jumped more than 38% in premarket trading on Friday after its FY2026 guidance came in above expectations, boosted by higher sales of its drug Linzess, which is used to treat constipation.The biotechnology company said it expects FY2026 revenue in the range of $450 million to $475 million, higher than analyst expectations of $319.5 million, according to data from Fiscal.ai.&nbsp;The outlook assumes net sales of Linzess will be between $1.125 billion and $1.175 billion in FY2026, driven by improved net price and low-single-digit demand growth, the company said.&nbsp;“We believe our full-year 2026 guidance demonstrates the significant progress we’ve made to deliver on these priorities to help drive value for shareholders moving forward,” it stated.&nbsp;<h2 class="st-heading-2">Linzess’ Potential</h2>In November, the U.S. Food and Drug Administration approved Ironwood’s Linzess capsules for pediatric patients aged seven and older with irritable bowel syndrome with constipation.Linzess is the first treatment approved for the disease in pediatric patients, the FDA had said at the time. Irritable bowel syndrome with constipation (IBS-C) is a common functional gastrointestinal disorder characterized by recurrent abdominal pain associated with infrequent, hard-to-pass stools. The contributing factors to the condition are typically multiple.Linzess is already approved for the treatment of adult patients with the condition. The FDA had noted that the safety and efficacy of Linzess were similar in clinical studies for both adults and pediatric patients.“Throughout 2025, we made significant progress in maximizing LINZESS while delivering sustained profits and cash flows in an effort to strengthen our financial position and maintain compliance with debt covenants over the coming quarters,” said Tom McCourt, chief executive officer of Ironwood. “We expect higher net sales in 2026 for LINZESS year-over-year,” he added.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around IRWD trended in ‘bullish’ territory amid ‘high’ message volumes.&nbsp;<figure class="image"><img style="aspect-ratio:632/64;" src="https://news.stocktwits-cdn.com/irwd_2_PNG_f7f4732ebe.webp" alt="Retail sentiment around IRWD trended in ‘bullish’ territory amid ‘high’ message volumes. " width="632" height="64"></figure>One user wondered whether the stock will hit the $10 mark.&nbsp;<figure class="image"><img style="aspect-ratio:667/154;" src="https://news.stocktwits-cdn.com/irwd_PNG_26af83bb21.webp" alt="One user wondered whether the stock will hit the $10 mark. " width="667" height="154"></figure>&nbsp;Shares in the IRWD fell 25.1% in 2025.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

The Linzess Room at Ironwood Pharmaceuticals in Cambridge, MA on April 20, 2018. (Photo by Craig F. Walker/The Boston Globe via Getty Images)

Why Did Ironwood Pharmaceuticals Stock Skyrocket Today?

The company announced on Friday that it expects FY2026 revenue in the $450 million to $475 million range. 

<ul class="summary-bullets"><li>While the discontinued trial yielded early and sustained anti-tumor responses, next generation G12C inhibitors are establishing a new benchmark with higher response rates, Verastem CMO said.&nbsp;</li><li>Verastem said it will now focus its resources on the clinical development of VS-7375 in advanced NSCLC and other solid tumors.&nbsp;</li><li>VS-7375 demonstrated a 69% response rate in advanced KRAS G12D NSCLC.</li></ul> Shares of Verastem Oncology (VSTM) fell 2% after hours on Monday after the company said that it has decided to discontinue its trial in advanced KRAS G12C-mutated non-small cell lung cancer (NSCLC) following evaluation of interim data.No more patients will be enrolled in the trial being conducted in collaboration with Amgen and those already enrolled can continue treatment as per the investigator's discretion, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20251229302295/en/Verastem-Oncology-Provides-Update-on-RAMP-203-Phase-12-Clinical-Trial-for-Advanced-KRAS-G12C-Mutant-Non-Small-Cell-Lung-Cancer">said</a>. The trial was evaluating Avutometinib and Amgen’s Sotorasib in a “doublet combination” and also with Defactinib as a “triplet combination” in patients naïve to or previously treated with a KRAS G12C inhibitor, which is a targeted cancer drug that block the specific KRAS G12C mutation.The company said it is assessing opportunities to share data from the interim analysis in the future. &nbsp;<h2 class="st-heading-2">Fresh Focus</h2>Verastem said it will now focus its resources on the clinical development of VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, in advanced NSCLC and other solid tumors while also evaluating Avutometinib plus Defactinib in combination with chemotherapy in first line metastatic pancreatic cancer.“While avutometinib plus defactinib combined well with a G12C inhibitor to drive early and sustained anti-tumor responses, next generation G12C inhibitors are establishing a new benchmark with higher response rates,” chief medical officer John Hayslip said.Hayslip added that VS-7375 demonstrated a 69% response rate in advanced KRAS G12D NSCLC.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around VSTM jumped from ‘bearish’ to ‘bullish’ territory over the past 24 hours while message volume stayed at ‘low’ levels.A Stocktwits user applauded the decision as “sound.”<stembedurl>https://www.stocktwits.com/Drew613/message/640355285</stembedurl>Another opined that the VS-7375 numbers are “very exciting” and said they could see why the company prioritized it over the discontinued trial.<stembedurl>https://www.stocktwits.com/Sawnchey/message/640352752</stembedurl><a href="https://stocktwits.com/symbol/VSTM">VSTM stock</a> has gained 50% this year and more than doubled over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-supplier-reportedly-slashes-contract-in-part-due-to-lower-than-expected-cybertruck-demand/cL7dT7ARExx">Tesla Supplier Reportedly Slashes Contract In Part Due To Lower-Than-Expected Cybertruck Demand</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the Verastem Oncology logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Verastem Oncology Stock Drops After Hours After Discontinuing A Clinical Trial In Lung Cancer

The company discontinued its trial in advanced KRAS G12C-mutated non-small cell lung cancer (NSCLC) following evaluation of interim data. 

<ul class="summary-bullets"><li>Afrezza revenue rose 23% to $18.49 million in the three months through the end of September, owing to higher prices and demand.&nbsp;</li><li>Revenue from the V-Go insulin delivery patch, however, slipped 19% to $3.8 million due to low demand.&nbsp;</li><li>MannKind’s adjusted earnings per share came in at $0.07, above an analyst estimate of $0.02, according to data from Fiscal AI.&nbsp; &nbsp;</li></ul>Shares of MannKind Corporation (MNKD) rose 8% on Wednesday after the company reported 17% growth in total revenue to $82.13 million, thanks to significant growth in its Afrezza inhaled insulin sales.Afrezza revenue <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/05/3181424/29517/en/MannKind-Corporation-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Business-Update.html">rose</a> 23% to $18.49 million in the three months through the end of September, owing to higher prices and demand, while royalties rose to $33.32 million. Revenue from the V-Go insulin delivery patch, however, slipped 19% to $3.8 million due to low demand.<h2 class="st-heading-2">Q3 Performance</h2>MannKind’s adjusted earnings per share came in at $0.07, up from $0.06 in the corresponding quarter of 2024, and above an analyst estimate of $0.02, according to data from Fiscal AI.The company ended the quarter with cash, cash equivalents, and investments of $286.3 million, after utilizing approximately $133.2 million and borrowing an additional $250 million to fund the <a href="https://stocktwits.com/news-articles/markets/equity/mannkind-corporation-to-acquire-scpharmaceuticals/chssVp5Rd1m">acquisition</a> of scPharmaceuticals, which was completed in October.The acquisition is expected to accelerate MannKind’s revenue growth with the addition of Furoscix to its portfolio. Furoscix is used to treat fluid overload in adult patients with chronic heart failure (CHF) and chronic kidney disease (CKD).“The acquisition of scPharmaceuticals marks a significant expansion of our commercial capabilities and is expected to accelerate growth of our product revenues and build upon our commitment to delivering innovative, patient-centric therapies,” said Michael Castagna, CEO of MannKind.The company has now submitted a supplementary application to the FDA for approval of Afrezza in the pediatric population aged four to 17 years. The agency is expected to make a decision on the application by May 29, 2026.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/MNKD">MNKD stock</a> fell from ‘bullish’ to ‘bearish’ territory over the past 24 hours, while message volume fell from ‘high’ to ‘normal’ levels.<figure class="image"><img style="aspect-ratio:624/61;" src="data:image/png;base64,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" width="624" height="61" alt="MNKD's Sentiment Meter and Message Volume as of 11:00 a.m. ET on Nov. 5, 2025 | Source: Stocktwits"><figcaption>MNKD's Sentiment Meter and Message Volume as of 11:00 a.m. ET on Nov. 5, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that Wednesday’s gain in stock price might not last.<stembedurl>https://stocktwits.com/nomalarkey/message/635009498</stembedurl>Another sounded optimistic about the stock’s prospects.<stembedurl>https://stocktwits.com/6Figs/message/635008031</stembedurl>MNKD stock is down 8% this year and approximately 18% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-executives-including-cfo-rally-for-musk-s-one-trillion-pay-package/cL2qZJZREGA">Tesla Executives Including CFO Rally For Musk’s $1T Pay Package</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Mannkind Corp and the company's inhalable insulin product. Company employee demonstrating how the device is used. (Photo by Lawrence K. Ho/Los Angeles Times via Getty Images)

MannKind Stock Soared 8% Today: Why A Surge In Afrezza Inhaled Insulin Sales Matters

The company has now also submitted a supplementary application to the FDA for approval of Afrezza in the pediatric population aged 4-17 years.

Current Price	$54.24
Prev Close	$53.51
Open	$53.33
Dividend Yield	N/A
50-Day Moving Average	$58.64
Beta	N/A
Avg. Volume	1.6M
PE Ratio	N/A

52-Week High	$70.61
52-Week Low	$21.25
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

URTY
ProShares UltraPro Russell2000

Feed

News

Sentiment

Fundamentals

Info

Latest URTY News

URTYProShares UltraPro Russell2000